Here we provide evidence that targeting the Hh pathway using the clinically investigated SMO inhibitor LDE225 in combination with nilotinib is an effective strategy for targeting CP-CML LSC. Here, CP is linked to chronic myelogenous leukemia, BCR-ABL1 positive.